Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.

Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study.

J Infect Dis. 2015 Jan 15;211(2):178-86. doi: 10.1093/infdis/jiu417. Epub 2014 Jul 31.

PMID:
25081936
2.

High seropositivity of IgG and IgM antibodies against cytomegalovirus (CMV) among HIV-1 seropositive patients in Ilorin, Nigeria.

Fowotade A, Okonko IO, Agbede OO, Suleiman ST.

Afr Health Sci. 2015 Mar;15(1):1-9. doi: 10.4314/ahs.v15i1.1.

3.

Positive results of immunoglobulin G cytomegalovirus serologic testing and risk of severe non-AIDS-related complications in HIV-infected patients.

Manfredi R.

J Infect Dis. 2015 Apr 15;211(8):1356-7. doi: 10.1093/infdis/jiu617. Epub 2014 Nov 7. No abstract available.

PMID:
25381369
4.

Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India.

Chakraborty A, Mahapatra T, Mahapatra S, Ansari S, Siddhanta S, Banerjee S, Banerjee D, Sarkar RN, Guha SK, Chakraborty N.

PLoS One. 2015 Feb 13;10(2):e0117466. doi: 10.1371/journal.pone.0117466. eCollection 2015.

5.

[The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].

Cartón JA, Maradona JA, de Oña M, Asensi V, Melón S, García-Alcalde ML, Rodríguez-Junquera M, Moreno-Torrico A, de Zárraga M.

Med Clin (Barc). 1999 Sep 4;113(6):205-9. Spanish.

PMID:
10472608
6.

Sexual factors associated with cytomegalovirus seropositivity in human immunodeficiency virus-infected men. The Seroco Study Group.

Carré N, Robain M, Dussaix E, Salmon-Ceron D, Meyer L.

Sex Transm Dis. 1997 Nov;24(10):582-6.

PMID:
9383847
7.

Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults.

Tripathi A, Liese AD, Winniford MD, Jerrell JM, Albrecht H, Rizvi AA, Zhang J, Duffus WA.

Clin Cardiol. 2014 Sep;37(9):517-22. doi: 10.1002/clc.22311.

8.

Role of cytomegalovirus sero-status in the development of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes.

Guech-Ongey M, Brenner H, Twardella D, Hahmann H, Rothenbacher D.

Int J Cardiol. 2006 Jul 28;111(1):98-103. Epub 2005 Oct 17.

PMID:
16229909
9.

Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus-infected hemophilia patients. National Cancer Institute Multicenter Hemophilia Cohort Study Group.

Rabkin CS, Hatzakis A, Griffiths PD, Pillay D, Ragni MV, Hilgartner MW, Goedert JJ.

J Infect Dis. 1993 Nov;168(5):1260-3.

PMID:
7710460
10.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
11.

Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study.

Moreno A, Cervera C, Fortún J, Blanes M, Montejo E, Abradelo M, Len O, Rafecas A, Martín-Davila P, Torre-Cisneros J, Salcedo M, Cordero E, Lozano R, Pérez I, Rimola A, Miró JM; OLT-HIV FIPSE Cohort Investigators.

Liver Transpl. 2012 Jan;18(1):70-81. doi: 10.1002/lt.22431.

12.

Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer-Norfolk cohort.

Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ.

Clin Infect Dis. 2013 May;56(10):1421-7. doi: 10.1093/cid/cit083. Epub 2013 Feb 26.

13.

Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1.

Doyle M, Atkins JT, Rivera-Matos IR.

Pediatr Infect Dis J. 1996 Dec;15(12):1102-6.

PMID:
8970220
14.

Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS.

Chan IS, Neaton JD, Saravolatz LD, Crane LR, Osterberger J.

AIDS. 1995 Oct;9(10):1145-51.

PMID:
8519450
15.

Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.

Bronke C, Palmer NM, Jansen CA, Westerlaken GH, Polstra AM, Reiss P, Bakker M, Miedema F, Tesselaar K, van Baarle D.

J Infect Dis. 2005 Mar 15;191(6):873-80. Epub 2005 Jan 31.

PMID:
15717261
16.

Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial.

Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M, Flanigan TP, McMahon DK, Sacks HS, Kennedy MS, Holland PV; Viral Activation Transfusion Study Group.

JAMA. 2001 Mar 28;285(12):1592-601.

PMID:
11268267
17.

Cytomegalovirus viremia in dried blood spots is associated with an increased risk of death in HIV-infected patients: a cohort study from rural Tanzania.

Brantsæter AB, Johannessen A, Holberg-Petersen M, Sandvik L, Naman E, Kivuyo SL, Rollag H, Bruun JN, Kvale D.

Int J Infect Dis. 2012 Dec;16(12):e879-85. doi: 10.1016/j.ijid.2012.08.003. Epub 2012 Sep 30.

18.

Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).

Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, Polsky B; AIDS Clinical Trials Group Protocol 360 Study Team.

Clin Infect Dis. 2003 Aug 15;37(4):567-78. Epub 2003 Jul 29.

PMID:
12905142
19.

Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.

Villacres MC, Lacey SF, La Rosa C, Krishnan R, Auge C, Longmate J, Zaia JA, Leedom JM, Diamond DJ.

J Infect Dis. 2001 Aug 1;184(3):256-67. Epub 2001 Jul 10.

PMID:
11443550
20.

A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.

Brosgart CL, Louis TA, Hillman DW, Craig CP, Alston B, Fisher E, Abrams DI, Luskin-Hawk RL, Sampson JH, Ward DJ, Thompson MA, Torres RA.

AIDS. 1998 Feb 12;12(3):269-77.

PMID:
9517989

Supplemental Content

Support Center